# Aytu BioPharma Inc. (AYTU)

Source: https://www.quantisnow.com/company/AYTU
Generated: 2026-11-18T10:14:16.385Z

- Ticker: AYTU
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001385818
- Website: aytubio.com

## About

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

## Latest AYTU news and filings

- 2026-11-17 12:57 UTC [Analyst Downgrade] [Aytu BioScience downgraded by Lake Street with a new price target](https://www.quantisnow.com/insight/aytu-bioscience-downgraded-by-lake-street-with-a-new-price-6795774)
- 2026-11-16 21:23 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-aytu-biopharma-inc-6794431)
- 2026-11-16 21:03 UTC [SEC Form 425] [SEC Form 425 filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-aytu-biopharma-inc-6794322)
- 2026-11-16 21:17 UTC [SEC Form 8-K] [Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aytu-biopharma-inc-filed-sec-form-8-k-results-of-operations-6794202)
- 2026-11-16 21:15 UTC [Market Insight] [Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results](https://www.quantisnow.com/insight/aytu-biopharma-reports-fiscal-2027-first-quarter-operational-and-financial-6794085)
- 2026-11-16 21:11 UTC [Mergers & Acquisitions] [Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion](https://www.quantisnow.com/insight/rosemont-pharmaceuticals-to-acquire-aytu-biopharma-to-accelerate-us-expansion-6794037)
- 2026-11-16 21:03 UTC [SEC Form 8-K] [Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aytu-biopharma-inc-filed-sec-form-8-k-entry-into-a-6793971)
- 2026-11-16 21:01 UTC [Market Insight] [Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer](https://www.quantisnow.com/insight/rosemont-pharmaceuticals-to-acquire-aytu-biopharma-in-all-cash-tender-offer-6793871)
- 2026-11-10 21:15 UTC [Market Insight] [Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026](https://www.quantisnow.com/insight/aytu-biopharma-to-report-fiscal-2027-first-quarter-operational-and-6784225)
- 2026-11-10 09:48 UTC [FDA Approval for ZOLPIMIST issued to AYTU](https://www.quantisnow.com/insight/fda-approval-for-zolpimist-issued-to-aytu-6782407)
- 2026-10-27 20:31 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aytu-biopharma-inc-6759528)
- 2026-10-22 20:30 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-aytu-biopharma-inc-6755365)
- 2026-09-22 20:14 UTC [SEC Form 10-K] [SEC Form 10-K filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-aytu-biopharma-inc-6723053)
- 2026-09-22 20:05 UTC [SEC Form 8-K] [Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aytu-biopharma-inc-filed-sec-form-8-k-results-of-operations-6722923)
- 2026-09-22 20:05 UTC [Market Insight] [Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results](https://www.quantisnow.com/insight/aytu-biopharma-reports-fiscal-2026-full-year-and-fourth-quarter-6722913)
- 2026-09-16 20:30 UTC [Market Insight] [Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026](https://www.quantisnow.com/insight/aytu-biopharma-to-report-fiscal-2026-full-year-and-fourth-6717682)
- 2026-08-14 16:08 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-aytu-biopharma-inc-6682486)
- 2026-07-30 20:34 UTC [SEC Form 4] [Chief Commercial Officer Pyszczymuka Greg was granted 20,000 shares, increasing direct ownership by 55% to 56,102 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-pyszczymuka-greg-was-granted-20000-shares-increasing-6656447)
- 2026-07-30 20:34 UTC [SEC Form 4] [Chief Executive Officer Disbrow Joshua R. was granted 30,000 shares, increasing direct ownership by 14% to 237,203 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-disbrow-joshua-r-was-granted-30000-shares-6656442)
- 2026-07-30 20:33 UTC [SEC Form 4] [Chief Business Officer Disbrow Jarrett was granted 15,000 shares, increasing direct ownership by 24% to 76,568 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-disbrow-jarrett-was-granted-15000-shares-increasing-6656436)
- 2026-07-30 20:33 UTC [SEC Form 4] [Chief Financial Officer Selhorn Ryan J was granted 25,000 shares, increasing direct ownership by 50% to 74,743 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-selhorn-ryan-j-was-granted-25000-shares-6656433)
- 2026-07-30 20:32 UTC [SEC Form 4] [Director Liu Vivian H was granted 10,000 shares, increasing direct ownership by 50% to 29,825 units (SEC Form 4)](https://www.quantisnow.com/insight/director-liu-vivian-h-was-granted-10000-shares-increasing-direct-6656429)
- 2026-07-30 20:31 UTC [SEC Form 4] [Director Jain Abhinav was granted 10,000 shares, increasing direct ownership by 51% to 29,500 units (SEC Form 4)](https://www.quantisnow.com/insight/director-jain-abhinav-was-granted-10000-shares-increasing-direct-ownership-6656420)
- 2026-07-30 20:31 UTC [SEC Form 4] [Director Dockery Carl was granted 10,000 shares, increasing direct ownership by 47% to 31,152 units (SEC Form 4)](https://www.quantisnow.com/insight/director-dockery-carl-was-granted-10000-shares-increasing-direct-ownership-6656419)
- 2026-07-30 20:31 UTC [SEC Form 4] [Director Donofrio John Jr. was granted 10,000 shares, increasing direct ownership by 73% to 23,762 units (SEC Form 4)](https://www.quantisnow.com/insight/director-donofrio-john-jr-was-granted-10000-shares-increasing-direct-6656417)
- 2026-06-25 20:31 UTC [SEC Form 8-K] [Aytu BioPharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement](https://www.quantisnow.com/insight/aytu-biopharma-inc-filed-sec-form-8-k-termination-of-a-6616050)
- 2026-06-01 20:15 UTC [Market Insight] [Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026](https://www.quantisnow.com/insight/aytu-biopharma-to-present-at-the-planet-microcap-las-vegas-6581756)
- 2026-05-18 20:05 UTC [Market Insight] [Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026](https://www.quantisnow.com/insight/aytu-biopharma-to-participate-in-the-lytham-partners-spring-2026-6560058)
- 2026-05-13 20:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-aytu-biopharma-inc-6550796)
- 2026-05-13 20:05 UTC [SEC Form 8-K] [Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aytu-biopharma-inc-filed-sec-form-8-k-results-of-operations-6550740)
- 2026-05-13 20:05 UTC [Market Insight] [Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results](https://www.quantisnow.com/insight/aytu-biopharma-reports-fiscal-2026-third-quarter-operational-and-financial-6550666)
- 2026-05-06 20:05 UTC [Market Insight] [Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026](https://www.quantisnow.com/insight/aytu-biopharma-to-report-fiscal-2026-third-quarter-operational-and-6535172)
- 2026-04-02 20:08 UTC [SEC Form 8-K] [Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aytu-biopharma-inc-filed-sec-form-8-k-entry-into-a-6484553)
- 2026-02-17 18:31 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-aytu-biopharma-inc-6395392)
- 2026-02-03 21:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Aytu BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-aytu-biopharma-inc-6372287)
- 2026-02-03 21:05 UTC [SEC Form 8-K] [Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aytu-biopharma-inc-filed-sec-form-8-k-results-of-operations-6372226)
- 2026-02-03 21:05 UTC [Market Insight] [Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results](https://www.quantisnow.com/insight/aytu-biopharma-reports-fiscal-2026-second-quarter-operational-and-financial-6372166)
- 2026-01-27 21:05 UTC [Market Insight] [Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026](https://www.quantisnow.com/insight/aytu-biopharma-to-report-fiscal-2026-second-quarter-operational-and-6362185)
- 2026-01-20 21:05 UTC [SEC Form 8-K] [Aytu BioPharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aytu-biopharma-inc-filed-sec-form-8-k-regulation-fd-disclosure-6354039)
- 2026-01-20 21:05 UTC [Market Insight] [Aytu BioPharma Recaps Investor Day Held on January 20, 2026](https://www.quantisnow.com/insight/aytu-biopharma-recaps-investor-day-held-on-january-20-2026-6354004)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AYTU
- Earnings history: https://www.quantisnow.com/earnings/AYTU
- Dividend history: https://www.quantisnow.com/dividends/AYTU
- Insider transactions: https://www.quantisnow.com/insiders/AYTU
- Options chain: https://www.quantisnow.com/options/AYTU
- SEC 8-K filings only: https://www.quantisnow.com/company/AYTU/8-k
- RSS and alerts for AYTU: https://www.quantisnow.com/docs/rss-feeds.md
